Im sure the other products don't represent an significant danger to patients, otherwise they wouldn't be used. I am sure they are improving their products all the time as well.
Similar doesn't mean same, does it.
I notice you use the term 'could'
"it could be said that cardiocel is not materially different from its competitors."
Well you 'could' be right, or you 'could' be speculating or you 'could' be wrong.
You are definitely right on the expected uptake, maybe even less than the company expected.
I don't know why, it "could" just be the normal uptake for new products in this market space.
Time will tell.
Ann: Admedus to Host Investor Webinar-AHZ.AX, page-16
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.90 |
Change
-0.100(1.00%) |
Mkt cap ! $208.2M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $45.07K | 4.592K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 813 | $9.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 554 | 1 |
View Market Depth
| Last trade - 11.44am 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |